The targets of interest include isocitrate dehydrogenase-1 (IDH1), fibroblast growth factor receptor-2 (FGFR2), human epidermal growth factor receptor-2 (HER2/ERBB2), protooncogene B-Raf (BRAF), high tumor mutational burden (TMB-H), high microsatellite instability or mismatch repair deficient (MSI-H/dMMR), neurotrophic tyrosine receptor kinase (NTRK) fusions, and RET fusions (Table 2). Here, ERBB2 is linked to neoplasm.